Use of Disinfection Cap to Reduce Central-Line–Associated Bloodstream Infection and Blood Culture Contamination Among Hematology–Oncology Patients

Mini Kamboj A1 A3 A4 C1, Rachel Blair A1, Natalie Bell A1 A2, Crystal Son A1, Yao-Ting Huang A3, Mary Dowling A2, Allison Lipitz-Snyderman A5, Janet Eagan A1 and Kent Sepkowitz A1 A3 A4

A1 Infection Control and Infectious Disease Service Memorial Sloan Kettering Cancer Center, New York, New York
A2 Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, New York
A3 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
A4 Department of Medicine, Weill Cornell Medical College, New York, New York
A5 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

OBJECTIVE
In this study, we examined the impact of routine use of a passive disinfection cap (SwabCap®, ICU Medical Inc., San Clemente, CA) for catheter hub decontamination in hematology–oncology patients.

SETTING
A tertiary care cancer center in New York City

METHODS
In this multiphase prospective study, we used 2 preintervention phases (P1 and P2) to establish surveillance and baseline rates followed by sequential introduction of disinfection caps on high-risk units (HRUs: hematologic malignancy wards, hematopoietic stem cell transplant units and intensive care units) (P3) and general oncology units (P4). Unit-specific and hospital-wide hospital-acquired central-line–associated bloodstream infection (HA-CLABSI) rates and blood culture contamination (BCC) with coagulase negative staphylococci (CONS) were measured.

RESULTS
Implementation of a passive disinfection cap resulted in a 34% decrease in hospital-wide HA-CLABSI rates (combined P1 and P2 baseline rate of 2.66–1.75 per 1,000 catheter days at the end of the study period). This reduction occurred only among high-risk patients and not among general oncology patients. In addition, the use of the passive disinfection cap resulted in decreases of 63% (HRUs) and 51% (general oncology units) in blood culture contamination, with an estimated reduction of 242 BCCs with CONS. The reductions in HA-CLABSI and BCC correspond to an estimated annual savings of $3.2 million in direct medical costs.

CONCLUSION
Routine use of disinfection caps is associated with decreased HA-CLABSI rates among high-risk hematology oncology patients and a reduction in blood culture contamination among all oncology patients.